Glyceryl Benzoate Esters Sustained Release Glycine Encephalopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glycine encephalopathy, such as sodium benzoate, require frequent administration due to rapid metabolism and excretion, leading to high doses and adverse effects like drowsiness in patients.
Innovation Solution
The use of glyceryl tribenzoate and glyceryl dibenzoate as sustained-release formulations that slowly convert to sodium benzoate in the body, allowing for reduced administration frequency and improved patient compliance, potentially inhibiting the progression of glycine encephalopathy with a single daily or twice-daily regimen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium benzoate is administered frequently (3-4 times per day), then therapeutic effect is maintained, but patient compliance deteriorates and adverse effects increase
Solution Approach 1:
The patent changes the chemical form of benzoate from sodium salt to glyceryl esters (dibenzoate and tribenzoate), which have different pharmacokinetic properties. These esters are hydrolyzed in the body to release benzoate slowly, extending the duration of action from several hours to 24 hours or more, thereby reducing dosing frequency while maintaining therapeutic effect
Solution Approach 2:
The glyceryl esters serve as pre-formed reservoirs of benzoate that are stored in the body and gradually converted to active form. This preliminary action allows the drug to be administered less frequently while still maintaining continuous therapeutic levels, as the ester prodrugs slowly release benzoate over time
2Reliability
If high doses of sodium benzoate are administered, then therapeutic effect is improved, but adverse effects such as drowsiness increase
Solution Approach 1:
By changing from sodium benzoate to glyceryl esters, the patent achieves sustained release of benzoate at lower peak concentrations. This prevents the high-dose peaks that cause drowsiness and other adverse effects, while maintaining adequate therapeutic levels through extended duration of action
Solution Approach 2:
The glyceryl ester prodrugs act as intermediaries that carry benzoate in a less active, slower-releasing form. This intermediary approach allows the active compound to be delivered gradually at lower peak doses, reducing adverse effects while maintaining therapeutic efficacy through sustained release
3Reliability
If sodium benzoate is administered, then ammonia removal is achieved, but rapid metabolism and excretion require frequent dosing
Solution Approach 1:
The patent changes the pharmacokinetic parameters of benzoate by using glyceryl esters with slower hydrolysis rates. This extends the duration of action from several hours to 24 hours or more, allowing continuous ammonia removal capability while reducing dosing frequency
Solution Approach 2:
The glyceryl ester prodrugs provide continuous release of benzoate over 24 hours or longer, ensuring uninterrupted ammonia removal capability. This continuous action is achieved through the gradual hydrolysis of ester bonds in the body, maintaining therapeutic levels without gaps between doses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Glyceryl tribenzoate and glyceryl dibenzoate provide a sustained release of sodium benzoate, effectively inhibiting glycine encephalopathy progression with fewer doses, reducing adverse effects and improving treatment compliance by maintaining therapeutic levels over an extended period.
Implementation Method 1
glyceryl tribenzoate and/or glyceryl dibenzoate for the treatment of glycine encephalopathy
Data Source
AI summary
This disclosure relates to pharmaceutical compositions and formulations useful for inhibiting the progression of glycine encephalopathy. The pharmaceutical compositions and formulations may include glyceryl tribenzoate. The pharmaceutical compositions and formulations may include glyceryl dibenzoate. The pharmaceutical compositions and formulations may be orally administered to the patient.